Literature DB >> 9747677

Visual outcomes following lensectomy and vitrectomy for combined anterior and posterior persistent hyperplastic primary vitreous.

R A Mittra1, L T Huynh, M S Ruttum, W F Mieler, T B Connor, D P Han, J S Pulido, S Dev.   

Abstract

OBJECTIVE: To determine the visual outcome after surgery for persistent hyperplastic primary vitreous using modern vitreoretinal techniques.
DESIGN: Retrospective medical record review during a 5-year period (June 1992 to June 1997). Information recorded for each patient included age, medical history, sex, results of preoperative ocular examination, age at diagnosis, procedure performed, intraoperative and postoperative complications, location and number of sclerotomy sites, type of aphakic rehabilitation, amblyopic therapy given, final visual acuity, and length of follow-up.
RESULTS: Fourteen patients who underwent surgical management of combined anterior and posterior persistent hyperplastic primary vitreous were identified. Eleven patients underwent aphakic rehabilitation and aggressive amblyopic therapy consisting of occlusive therapy for several waking hours each day. One additional older patient received aphakic rehabilitation only. Ten eyes (71%) achieved a visual acuity of 20/300 or better, and 8 (57%) obtained a final visual acuity of 20/100 or better. Average length of follow-up was 22 months (range, 4-57 months). Nine patients were fitted with an aphakic soft contact lens, 2 older patients had a posterior chamber intraocular lens placed at the time of vitrectomy, and 1 patient wore aphakic spectacles.
CONCLUSIONS: With modern vitreoretinal techniques, aphakic rehabilitation, and aggressive amblyopic therapy, useful vision can be obtained in the majority of patients with combined anterior and posterior persistent hyperplastic primary vitreous.

Entities:  

Mesh:

Year:  1998        PMID: 9747677     DOI: 10.1001/archopht.116.9.1190

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Outcomes in persistent hyperplastic primary vitreous.

Authors:  A Hunt; N Rowe; A Lam; F Martin
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Unilateral persistent hyperplastic primary vitreous: intensive management approach with excellent outcome beyond visual maturation.

Authors:  Imran H Yusuf; Chetan Kantibhai Patel; John F Salmon
Journal:  BMJ Case Rep       Date:  2015-01-06

3.  Infant Aphakia Treatment Study: effects of persistent fetal vasculature on outcome at 1 year of age.

Authors:  David G Morrison; M Edward Wilson; Rupal H Trivedi; Scott R Lambert; Michael J Lynn
Journal:  J AAPOS       Date:  2011-10       Impact factor: 1.220

4.  Unoperated eyes with persistent fetal vasculature.

Authors:  Nishi Gulati; Ralph C Eagle; William Tasman
Journal:  Trans Am Ophthalmol Soc       Date:  2003

5.  Intraocular lens implantation in combination with lensectomy and vitrectomy for persistent fetal vasculature.

Authors:  Jiao Lyu; Peiquan Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-11       Impact factor: 3.117

6.  Surgical treatment of persistent fetal vasculature and visual rehabilitation: one-year followup.

Authors:  N Kozeis; K T Tsaousis; D Gidaris
Journal:  Case Rep Med       Date:  2012-02-06

Review 7.  Innovations in pediatric cataract surgery.

Authors:  Sudarshan Kumar Khokhar; Ganesh Pillay; Esha Agarwal; Manish Mahabir
Journal:  Indian J Ophthalmol       Date:  2017-03       Impact factor: 1.848

8.  Outcomes and surgical management of persistent fetal vasculature.

Authors:  Nikhila Khandwala; Cagri Besirli; Brenda L Bohnsack
Journal:  BMJ Open Ophthalmol       Date:  2021-04-29

Review 9.  Major challenges in vitreoretinal surgery.

Authors:  Yijun Hu; Shibo Tang
Journal:  Taiwan J Ophthalmol       Date:  2014-07-26

10.  Repair of Traumatic Rhegmatogenous Retinal Detachment Combined with Congenital Falciform Retinal Detachment.

Authors:  Fukutaro Mano; Kuo-Chung Chang; Tomiya Mano
Journal:  Case Rep Ophthalmol       Date:  2018-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.